Overview
Healthcare apparel brand's Q1 revenue rose 28%, beating analyst expectations
Adjusted EBITDA for Q1 beat analyst expectations, margin improved to 8.7%
Company raised full-year 2026 outlook on continued growth and operational execution
Outlook
FIGS raises full-year 2026 net revenues growth outlook to 14%–16% vs 2025
Company expects full-year 2026 adjusted EBITDA margin of 13.0%–13.2%
FIGS sees Q2 net revenues growth in low 20% range, driven by active customers and AOV
Result Drivers
CUSTOMER GROWTH - Co said revenue growth was primarily driven by increases in orders from new and existing customers and higher average order value
INTERNATIONAL STRENGTH - International net revenues rose 49.9% year over year, outpacing U.S. growth
OPERATING LEVERAGE - Operating expenses as a percentage of revenue declined due to fixed cost leverage, lower stock-based compensation, and reduced fulfillment and shipping expenses, partially offset by higher marketing costs
Company press release: ID:nBw4YmHV1a
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$159.90 mln
$153 mln (8 Analysts)
Q1 Net Income
$6.30 mln
Q1 Adjusted EBITDA
Beat
$13.90 mln
$11.04 mln (7 Analysts)
Q1 Adjusted EBITDA Margin
8.70%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the apparel & accessories peer group is "buy"
Wall Street's median 12-month price target for Figs Inc is $17.50, about 20.7% above its May 6 closing price of $14.50
The stock recently traded at 54 times the next 12-month earnings vs. a P/E of 89 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)